PT Kimia Farma Tbk (KAEF) has held a General Meeting of Shareholders for Financial Year 2022 (RUPSTB) which was held offline and online (hybrid) attended by KAEF shareholders and held electronically with an e-proxy system provided by the Indonesian Central Securities Depository (KSEI).
The Company managed to reduce its cost of goods sold so that it could decrease on an annualized basis in the first quarter of 2020 to Rp 1.44 trillion. Thus, KAEF successfully posted a gross profit growth of 14% to Rp858.58 billion. KAEF posted a total profit for the year that can be distributed to owners of the parent entity and non-controlling interests of Rp24.63 billion in the first quarter of 2023. This realization increased compared to the same period in the previous year of Rp2.58 billion.
Shortly after the 2022 RUPSTB, Kimia Farma held a 2023 Public Expose which was attended by media partners. In the agenda, it was conveyed that in 2023, KAEF will continue to carry out business development strategies including accelerating product and service innovation, as well as strengthening businesses such as strengthening the end-to-end business portfolio and developing the vitamin, mineral and supplement (VMS) product category, strategic partnerships with local and global institutions, and developing products in Anatomical Therapeutic Class 2 (ATC-2).
David Utama said that several positive achievements obtained by the company this year cannot be separated from management policies in implementing operational excellence with a path to profitability and human resource transformation. So it is not surprising that KAEF managed to record an improvement in the sales portfolio of high-margin products, namely ethical and generic products. This made the Company manage to record a positive EBITDA by reaching Rp238.97 billion.
